Evidence map›Paper›PMID 37460269›Full record

SynthesisOpen heart2023

Systematic review of the incidence and clinical risk predictors of atrial fibrillation and permanent pacemaker implantation for bradycardia in Fabry disease.

Ravi Vijapurapu, Ashwin Roy, Polyvios Demetriades, Adrian Warfield, Derralynn A Hughes, James Moon, Peter Woolfson, Joseph de Bono, Tarekegn Geberhiwot, Dipak Kotecha and 1 more

Open access · goldAbstract readSystematic Review
In one paragraph

Synthesis in Open heart, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Review
  3. Fabry Disease: A Focus on the Role of Oxidative Stress.Antioxidants (Basel, Switzerland) · 2026
    Review
  4. Article
  5. Early Atrial Remodeling Drives Arrhythmia in Fabry Disease.Circulation. Arrhythmia and electrophysiology · 2025
    Article
  6. Article
  7. Review
  8. Arrhythmogenesis in Fabry Disease.Current cardiology reports · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Ravi VijapurapuInstitute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK.
Ashwin RoyInstitute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK.ORCID 0000-0003-4600-2733
Polyvios DemetriadesDepartment of Cardiology, Queen Elizabeth Hospital, Birmingham, UK.
Adrian WarfieldDepartment of Histopathology, Queen Elizabeth Hospital, Birmingham, UK.
Derralynn A HughesUniversity College London, London, UK.
James MoonDepartment of Cardiology, Saint Bartholomew's Hospital Barts Heart Centre, London, UK.
Peter WoolfsonDepartment of Cardiology, Salford Royal Hospital, Salford, UK.
Joseph de BonoDepartment of Cardiology, Queen Elizabeth Hospital, Birmingham, UK.
Tarekegn GeberhiwotDepartment of Metabolic Medicine, Queen Elizabeth Hospital, Birmingham, UK.
Dipak KotechaInstitute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK.ORCID 0000-0002-2570-9812
Richard Paul SteedsInstitute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK rick.steeds@uhb.nhs.uk.ORCID 0000-0001-5687-2535
Queen Elizabeth Hospital Birmingham · GBUniversity of Birmingham · GBSalford Royal Hospital · GBSt Bartholomew's Hospital · GBUniversity College London · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionFabry disease (FD) is an X-linked lysosomal storage disorder caused by enzyme deficiency, leading to glycosphingolipid accumulation. Cardiac accumulation triggers local tissue injury, electrical instability and arrhythmia. Bradyarrhythmia and atrial fibrillation (AF) incidence are reported in up to 16% and 13%, respectively.

objectiveWe conducted a systematic review evaluating AF burden and bradycardia requiring permanent pacemaker (PPM) implantation and report any predictive risk factors identified.

methodsWe conducted a literature search on studies in adults with FD published from inception to July 2019. Study outcomes included AF or bradycardia requiring therapy. Databases included Embase, Medline, PubMed, Web of Science, CINAHL and Cochrane. The Risk of Bias Agreement tool for Non-Randomised Studies (RoBANS) was utilised to assess bias across key areas.

results11 studies were included, eight providing data on AF incidence or PPM implantation. Weighted estimate of event rates for AF were 12.2% and 10% for PPM. Age was associated with AF (OR 1.05-1.20 per 1-year increase in age) and a risk factor for PPM implantation (composite OR 1.03). Left ventricular hypertrophy (LVH) was associated with AF and PPM implantation.

conclusionEvidence supporting AF and bradycardia requiring pacemaker implantation is limited to single-centre studies. Incidence is variable and choice of diagnostic modality plays a role in detection rate. Predictors for AF (age, LVH and atrial dilatation) and PPM (age, LVH and PR/QRS interval) were identified but strength of association was low. Incidence of AF and PPM implantation in FD are variably reported with arrhythmia burden likely much higher than previously thought. PROSPERO DATABASE: CRD42019132045.

Indexed as

Atrial FibrillationFabry DiseasePacemaker, ArtificialAdultBradycardiaHumansIncidenceatrial fibrillationFabrymetabolic diseasespacemaker, artificial

Identifiers

PMID37460269
PMCPMC10357684
OpenAlexW4384501602

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.